<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: cannot market", fill: "#fae7b5"},
{source: "3: cannot market", target: "3: transgenically", fill: "#fae7b5"},
{source: "3: transgenically", target: "3: necessary regulatory", fill: "#fae7b5"},
{source: "3: cannot market", target: "4: transgenically", fill: "#cf71af"},
{source: "4: transgenically", target: "4: biological products", fill: "#cf71af"},
{source: "4: biological products", target: "4: collaborators", fill: "#cf71af"},
{source: "4: collaborators", target: "4: regulatory approvals", fill: "#cf71af"},
{source: "4: regulatory approvals", target: "4: from federal", fill: "#cf71af"},
{source: "4: from federal", target: "4: local governmental authorities", fill: "#cf71af"},
{source: "4: local governmental authorities", target: "4: countries such as", fill: "#cf71af"},
{source: "4: transgenically", target: "9: may impose restrictions", fill: "#f9429e"},
{source: "9: may impose restrictions", target: "9: demands on", fill: "#f9429e"},
{source: "9: demands on", target: "9: clinical trials", fill: "#f9429e"},
{source: "9: clinical trials", target: "9: additional resources", fill: "#f9429e"},
{source: "9: additional resources", target: "9: longer delays than", fill: "#f9429e"},
{source: "9: may impose restrictions", target: "17: regulatory approvals", fill: "#e7accf"},
{source: "17: regulatory approvals", target: "17: transgenically", fill: "#e7accf"},
{source: "17: transgenically", target: "17: timely manner", fill: "#e7accf"},
{source: "17: timely manner", target: "17: commercialize", fill: "#e7accf"},
{source: "17: commercialize", target: "17: commercialization may", fill: "#e7accf"},
{source: "17: commercialization may", target: "17: stock price will suffer", fill: "#e7accf"},
{source: "17: regulatory approvals", target: "23: such development will ultimately", fill: "#f1a7fe"},
{source: "23: such development will ultimately", target: "23: such approval will", fill: "#f1a7fe"},
{source: "23: such development will ultimately", target: "24: development", fill: "#c2b280"},
{source: "24: development", target: "24: indication", fill: "#c2b280"},
{source: "24: development", target: "34: additional capital", fill: "#f93"},
{source: "34: additional capital", target: "34: operations", fill: "#f93"},
{source: "34: operations", target: "34: development manufacturing", fill: "#f93"},
{source: "34: development manufacturing", target: "34: commercialization", fill: "#f93"},
{source: "34: additional capital", target: "39: additional capital", fill: "#fada5e"},
{source: "39: additional capital", target: "39: operations", fill: "#fada5e"},
{source: "39: operations", target: "39: development", fill: "#fada5e"},
{source: "39: development", target: "39: manufacturing", fill: "#fada5e"},
{source: "39: manufacturing", target: "39: commercialization", fill: "#fada5e"},
{source: "39: commercialization", target: "39: activities", fill: "#fada5e"},
{source: "39: additional capital", target: "42: cash requirements may vary materially from", fill: "#555d50"},
{source: "42: cash requirements may vary materially from", target: "42: development programs", fill: "#555d50"},
{source: "42: development programs", target: "42: competitive", fill: "#555d50"},
{source: "42: competitive", target: "42: technological advances", fill: "#555d50"},
{source: "42: technological advances", target: "42: future collaborations", fill: "#555d50"},
{source: "42: future collaborations", target: "42: regulatory requirements", fill: "#555d50"},
{source: "42: cash requirements may vary materially from", target: "43: additional financing through public", fill: "#006b3c"},
{source: "43: additional financing through public", target: "43: private sources", fill: "#006b3c"},
{source: "43: private sources", target: "43: equity financing", fill: "#006b3c"},
{source: "43: equity financing", target: "43: through collaborative", fill: "#006b3c"},
{source: "43: through collaborative", target: "43: arrangements with corporate partners", fill: "#006b3c"},
{source: "43: additional financing through public", target: "61: discoveries by others could", fill: "#c4c3d0"},
{source: "61: discoveries by others could", target: "61: technology", fill: "#c4c3d0"},
{source: "61: technology", target: "61: noncompetitive as", fill: "#c4c3d0"},
{source: "61: discoveries by others could", target: "217: obligations", fill: "#ffb347"},
{source: "217: obligations", target: "217: issue shares", fill: "#ffb347"},
{source: "217: issue shares", target: "217: common stock", fill: "#ffb347"},
{source: "217: common stock", target: "217: ownership interest", fill: "#ffb347"},
{source: "217: ownership interest", target: "217: may adversely affect", fill: "#ffb347"},
{source: "217: obligations", target: "START_HERE", fill: "#ffb347"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Negotiation</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Transgene">Transgene</a></td>
      <td>Transgender people have a gender identity or gender expression that differs from the sex that they were assigned at birth. Some transgender people who desire medical assistance to transition from one sex to another identify as transsexual.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetically_modified_organism">Genetically modified organism</a></td>
      <td>A genetically modified organism (GMO) is any organism whose genetic material has been altered using genetic engineering techniques. The exact definition of a genetically modified organism and what constitutes genetic engineering varies, with the most common being an organism altered in a way that "does not occur naturally by mating and/or natural recombination".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetically_modified_animal">Genetically modified animal</a></td>
      <td>Genetically modified animals are animals that have been genetically modified for a variety of purposes including producing drugs, enhancing yields, increasing resistance to disease, etc. The vast majority of genetically modified animals are at the research stage while the number close to entering the market remains small.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetically_modified_food">Genetically modified food</a></td>
      <td>Genetically modified foods (GM foods), also known as genetically engineered foods (GE foods), or bioengineered foods are foods produced from organisms that have had changes introduced into their DNA using the methods of genetic engineering. Genetic engineering techniques allow for the introduction of new traits as well as greater control over traits when compared to previous methods, such as selective breeding and mutation breeding.The discovery of DNA and the improvement of genetic technology in the 20th century played a crucial role in the development of transgenic technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetically_modified_crops">Genetically modified crops</a></td>
      <td>Genetically modified crops (GM crops) are plants used in agriculture, the DNA of which has been modified using genetic engineering methods. Plant genomes can be engineered by physical methods or by use of Agrobacterium for the delivery of sequences hosted in T-DNA binary vectors.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetically_modified_plant">Genetically modified plant</a></td>
      <td>Genetically modified plants have been engineered for scientific research, to create new colours in plants, deliver vaccines,  and to create enhanced crops. Plant genomes can be engineered by physical methods or by use of Agrobacterium for the delivery of sequences hosted in T-DNA binary vectors.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Transgenic_hydra">Transgenic hydra</a></td>
      <td>Cnidarians such as Hydra have become attractive model organisms to study the evolution of immunity. However, despite long-term efforts, stably transgenic animals could not be generated, severely limiting the functional analysis of genes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetically_modified_bacteria">Genetically modified bacteria</a></td>
      <td>Genetically modified bacteria were the first organisms to be modified in the laboratory, due to their simple genetics.  These organisms are now used for several purposes, and are particularly important in producing large amounts of pure human proteins for use in medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reporter_gene">Reporter gene</a></td>
      <td>In molecular biology, a reporter gene (often simply reporter) is a gene that researchers attach to a regulatory sequence of another gene of interest in bacteria, cell culture, animals or plants. Such genes are called reporters because the characteristics they confer on organisms expressing them are easily identified and measured, or because they are selectable markers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genetically_modified_tomato">Genetically modified tomato</a></td>
      <td>A genetically modified tomato, or transgenic tomato, is a tomato that has had its genes modified, using genetic engineering. The first trial genetically modified food was a tomato engineered to have a longer shelf life (the Flavr Savr), which was on the market briefly beginning on May 21, 1994.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GTC BIOTHERAPEUTICS INC      ITEM 1A RISK FACTORS        The following are <font color="blue">certain factors</font> that <font color="blue">could affect</font> our future results</td>
    </tr>
    <tr>
      <td><font color="blue">They     </font>should  be  considered  in  <font color="blue">connection with</font> evaluating forward-looking     statements made by us because these <font color="blue">factors could</font> cause <font color="blue">actual outcomes</font> and     results to <font color="blue">differ materially from</font> the outcomes and results as expressed in     those forward-looking statements</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR BUSINESS        We <font color="blue">cannot market</font> and sell our <font color="blue">transgenically</font> produced products in the United     States or in other countries if we fail to obtain the <font color="blue"><font color="blue">necessary</font> <font color="blue">regulatory</font></font>     approvals</td>
    </tr>
    <tr>
      <td>Before we can sell any <font color="blue">transgenically</font> produced drug or <font color="blue">biological products</font>     that we or our <font color="blue">collaborators</font> develop, we must receive <font color="blue"><font color="blue">regulatory</font> approvals</font>     <font color="blue">from federal</font>, state and <font color="blue">local <font color="blue">government</font>al authorities</font>, including the United     States Food and Drug Administration, or FDA, and similar agencies in other     countries, such as the European Medicines Agency, or EMEA, in Europe</td>
    </tr>
    <tr>
      <td>To     date, none of our <font color="blue">transgenically</font> produced compounds have <font color="blue">been approved</font> for     sale  in  the  United  States or any <font color="blue">foreign country</font></td>
    </tr>
    <tr>
      <td>Moreover, to our     knowledge, <font color="blue">no <font color="blue">therapeutic</font></font> protein produced in the milk of a transgenic     animal  has <font color="blue">been submitted</font> to the FDA or, except for our submission of     ATryn^^® to the EMEA, to any other <font color="blue"><font color="blue">regulatory</font> agency</font> for <font color="blue">final <font color="blue">regulatory</font></font>     approval</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font>required <font color="blue"><font color="blue">regulatory</font> approvals</font> for our <font color="blue">transgenically</font>     produced <font color="blue">products may</font> take <font color="blue">several years</font> to complete and is expensive and     uncertain</td>
    </tr>
    <tr>
      <td>It is possible that the FDA or any other <font color="blue"><font color="blue">regulatory</font> authority may</font>     not act quickly or <font color="blue">favorably on</font> our requests for approval or will require us     to <font color="blue">provide <font color="blue">additional</font> data</font> that we do not currently anticipate</td>
    </tr>
    <tr>
      <td>For example,     the FDA <font color="blue">may impose <font color="blue">restrictions</font></font> and <font color="blue">demands on</font> our <font color="blue">clinical trials</font> that     require <font color="blue"><font color="blue">additional</font> resources</font> and result in <font color="blue">longer delays than</font> we anticipate</td>
    </tr>
    <tr>
      <td>In addition, the FDA may require us to conduct further <font color="blue">clinical trials</font> and     post-marketing testing and surveillance to monitor the effects of approved     products</td>
    </tr>
    <tr>
      <td>The FDA or other <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities may</font> also</font> place <font color="blue">conditions</font>     on  approval  that  <font color="blue">could restrict</font> the <font color="blue">commercial <font color="blue">application</font>s</font> of such     products</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> extensive FDA or similar <font color="blue">regulations</font> may result in     delay, suspension or <font color="blue">cancellation</font> of a trial or a <font color="blue">regulatory</font> authority’s     refusal to <font color="blue">accept test</font> results</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities may</font> have varying     <font color="blue">interpretations</font> of our pre-clinical and clinical trial data, which could     delay,  limit  or  prevent  <font color="blue">regulatory</font>  approval or clearance</td>
    </tr>
    <tr>
      <td><font color="blue">Because     </font><font color="blue">transgenically</font> produced <font color="blue">products represent novel <font color="blue">therapeutic</font> products</font>, the     process for <font color="blue">regulatory</font> approval is unproven</td>
    </tr>
    <tr>
      <td>There may be <font color="blue"><font color="blue">additional</font> delays</font>     in <font color="blue">regulatory</font> approval due to issues arising from the breeding of transgenic     animals  and  the  use  of  proteins  <font color="blue">derived from them</font></td>
    </tr>
    <tr>
      <td>Any delays or     <font color="blue"><font color="blue">difficult</font>ies</font>   in  obtaining  <font color="blue">regulatory</font>  approval  or  clearance  for     <font color="blue">transgenically</font> produced <font color="blue">products may</font>:           •   <font color="blue"><font color="blue">adversely</font> affect</font> the marketing of any <font color="blue">transgenically</font> produced products     we or our <font color="blue">collaborators</font> develop;           •   <font color="blue">impose <font color="blue">significant</font> <font color="blue">additional</font> costs on us</font> or our <font color="blue">collaborators</font>;           •   diminish any <font color="blue"><font color="blue">competitive</font> <font color="blue">advantages</font></font> that we or our <font color="blue">collaborators</font> may     attain; and           •   limit our ability to receive royalties and <font color="blue">generate revenue</font> and     profits</td>
    </tr>
    <tr>
      <td>11     ______________________________________________________________________    [38]Table of <font color="blue">Contents       </font>If we do not receive <font color="blue"><font color="blue">regulatory</font> approvals</font> for our <font color="blue">transgenically</font> produced     products  in a <font color="blue">timely manner</font>, we will not be able to <font color="blue">commercialize</font> our     products,  or  their  <font color="blue"><font color="blue">commercialization</font> may</font> be limited or delayed and,     therefore, our business and <font color="blue">stock price will suffer</font></td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue">regulatory</font> approval for our <font color="blue">transgenically</font> produced     products,  the  FDA  or similar agencies in other <font color="blue">countries may impose</font>     <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> for which our <font color="blue">products may</font> be marketed</td>
    </tr>
    <tr>
      <td>These  <font color="blue">limitations could reduce</font> the size of the <font color="blue">potential market</font> for a     product</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  <font color="blue">comply with</font> applicable FDA and other <font color="blue">regulatory</font>     <font color="blue">requirements</font> can result in, among other things, warning letters, fines,     <font color="blue">injunctions</font>,  civil penalties, recall or seizure of products, total or     <font color="blue">partial suspension</font> of production, refusal of the <font color="blue">government</font> to renew our     <font color="blue">marketing <font color="blue">application</font>s</font> and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Our  MAA  for  ATryn^^® in the HD <font color="blue">indication</font> is currently subject to a     re-examination process in Europe after the CHMP issued a <font color="blue">negative opinion</font>     <font color="blue">recommending</font>  <font color="blue">against approval</font> of ATryn^^® for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>If our     <font color="blue">application</font> is not <font color="blue">approved by</font> EMEA upon re-examination, our MAA would     terminate and the <font color="blue">commercialization</font> of ATryn^^® in Europe <font color="blue">would likely</font> be     <font color="blue">delayed until</font> ATryn^^® is developed and approved for an acquired <font color="blue">deficiency</font>     <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>There is no assurance that <font color="blue">such <font color="blue">development</font> will ultimately</font> be     successful or that <font color="blue">such approval will</font> be obtained</td>
    </tr>
    <tr>
      <td>We filed an investigational new drug <font color="blue">application</font>, or IND, with the FDA in     2003 for clinical <font color="blue">development</font> of ATryn^^® in HD <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>In April 2005,     we received <font color="blue"><font color="blue">authorization</font> from</font> the FDA to begin a further clinical trial of     ATryn^^® under an <font color="blue">amended version</font> of our IND If we are able to conduct this     study  <font color="blue">successfully</font>  and on schedule, we currently anticipate filing a     Biologics License Application for ATryn^^® for the HD <font color="blue">indication</font> in the     <font color="blue"><font color="blue">United States</font> </font>in 2007</td>
    </tr>
    <tr>
      <td>Delays in completing our current ATryn^^® trial or in     obtaining FDA approval of ATryn^® could cause substantial delays in the     <font color="blue">commercialization</font> of ATryn^^®^ in the <font color="blue"><font color="blue">United States</font> </font>and <font color="blue"><font color="blue">adversely</font> affect</font> our     business and stock price</td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur <font color="blue">significant</font></font> operating losses for the next     <font color="blue">several years</font> and we <font color="blue">may never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td>We have had operating losses since our inception, and we expect losses to     continue  for  the  next  <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>From our inception in 1993 to     January 1, 2006, we have <font color="blue">incurred cumulative losses</font> of <font color="blue">approximately</font> dlra209dtta8     million</td>
    </tr>
    <tr>
      <td>These losses have resulted <font color="blue">principally from</font> the costs of our     research and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our net losses for <font color="blue">fiscal years</font> ended,     2003, 2004 and 2005, have been dlra29dtta5 million, dlra29dtta5 million, and dlra30dtta1     million, respectively</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">continue incurring <font color="blue">significant</font></font> operating     losses for at least the next <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We may never receive material     <font color="blue">revenues from product sales</font> or <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We will need <font color="blue"><font color="blue">additional</font> capital</font> to fund our <font color="blue">operations</font>, including research     and <font color="blue">development</font>, <font color="blue">manufacturing</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>If we do not have or     cannot raise <font color="blue"><font color="blue">additional</font> capital</font> when needed, we will be unable to develop     and <font color="blue">commercialize</font> our product programs <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>In  order to develop and bring our <font color="blue">transgenically</font> produced products to     market, we and our <font color="blue"><font color="blue">collaboration</font> partners must commit</font> substantial resources     to costly and time-consuming research, pre<font color="blue">clinical testing</font> and clinical     trials</td>
    </tr>
    <tr>
      <td>As  of January 1, 2006, we had dlra26dtta4 million in cash and cash     <font color="blue">equivalents</font> and dlra9dtta8 million in marketable securities, which were offset in     part by our dlra20dtta3 million in <font color="blue">current <font color="blue">liabilities</font></font></td>
    </tr>
    <tr>
      <td>We expect our <font color="blue">current cash</font>     resources and <font color="blue">milestone payments</font> and <font color="blue"><font color="blue">manufacturing</font> revenue</font> including those     from our <font color="blue"><font color="blue">agreement</font> with</font> LEO Pharma to be sufficient to fund <font color="blue">operations</font> to     mid 2007</td>
    </tr>
    <tr>
      <td>We will need <font color="blue"><font color="blue">additional</font> capital</font> to fund our <font color="blue">operations</font>, including     our  research  and  <font color="blue">development</font>,  <font color="blue">manufacturing</font>  and <font color="blue">commercialization</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If we do not have or cannot raise <font color="blue"><font color="blue">additional</font> capital</font> when     needed, we would be forced to delay, scale back or <font color="blue">eliminate one</font> or more of     our research and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>Our drug <font color="blue">development</font> programs and the further <font color="blue">development</font> of ATryn^® for     approvals in the <font color="blue"><font color="blue">United States</font> </font>will require substantial <font color="blue"><font color="blue">additional</font> cash</font> to     <font color="blue">fund expenses</font> that we will incur in <font color="blue"><font color="blue">connection with</font> preclinical studies</font> and     <font color="blue">clinical trials</font>, <font color="blue">regulatory</font> review, <font color="blue">manufacturing</font> and sales and marketing     efforts</td>
    </tr>
    <tr>
      <td>Our cash <font color="blue">requirements</font> may vary materially from those now planned,     depending  upon  the results of our research and <font color="blue">development</font> programs,     <font color="blue">competitive</font> and <font color="blue"><font color="blue">technological</font> advances</font>, the terms of <font color="blue">future <font color="blue"><font color="blue">collaboration</font>s</font></font>,     <font color="blue">regulatory</font> <font color="blue">requirements</font> and other factors</td>
    </tr>
    <tr>
      <td>We expect we will need to obtain     <font color="blue">additional</font> financing, through public or <font color="blue">private sources</font>, including debt or     <font color="blue">equity financing</font>, in addition to any funding obtained <font color="blue">through collaborative</font>     or other <font color="blue"><font color="blue">arrangements</font> with corporate partners</font></td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>on the state of the     capital markets, interest rates, our <font color="blue">financial profile</font> and other <font color="blue">factors at</font>     that time, we may not be able to obtain <font color="blue">adequate funds on</font> acceptable terms     when needed</td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise capital through</font> the sale of equity, or securities     convertible into equity, existing <font color="blue"><font color="blue">shareholder</font>s</font>’ proportionate ownership in     us will be reduced</td>
    </tr>
    <tr>
      <td>If we cannot obtain financing, we could be forced to     delay,  scale  back  or eliminate some of our research and <font color="blue">development</font>     programs</td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font>Our <font color="blue">transgenically</font> produced products other than ATryn^^®^ are at an early     stage of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developing </font><font color="blue">products based on transgenic <font color="blue">technology</font></font> is subject to <font color="blue">significant</font>     <font color="blue">development</font> risks</td>
    </tr>
    <tr>
      <td><font color="blue">Each DNA </font>construct is unique and it is possible that it     might not be expressed in the transgenic animal’s milk at a level that is     <font color="blue"><font color="blue">commercially</font> viable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Purifying </font>the <font color="blue">recombinant</font> protein out of the milk to     use as a <font color="blue">bio<font color="blue">therapeutic</font> may</font> be <font color="blue">too <font color="blue">difficult</font></font> to be <font color="blue"><font color="blue">commercially</font> feasible</font></td>
    </tr>
    <tr>
      <td>In     addition, production of the <font color="blue">recombinant</font> protein may have <font color="blue">negative effects on</font>     the health of either the <font color="blue">mammary gland</font> or more <font color="blue">systematically on</font> the animal     as a whole</td>
    </tr>
    <tr>
      <td>This <font color="blue">would compromise</font> the ability of the animal to produce the     <font color="blue">recombinant</font> protein</td>
    </tr>
    <tr>
      <td><font color="blue">Directing </font>the <font color="blue">mammary gland</font> to produce <font color="blue">additional</font>     proteins in the milk could <font color="blue"><font color="blue">negatively</font> affect</font> lactation, thereby shutting     <font color="blue">down milk production</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">mammary gland</font> may also modify a protein in such a     manner that it is non-functional or harmful to <font color="blue">human subjects</font></td>
    </tr>
    <tr>
      <td>It is also     possible that there may be <font color="blue">disease agents present</font> in goats or cows that     <font color="blue">would prevent</font> the use of <font color="blue">products derived from</font> these animals</td>
    </tr>
    <tr>
      <td>If an as yet     unknown disease was identified that could not be <font color="blue"><font color="blue">effective</font>ly</font> mitigated,     <font color="blue">government</font> agencies may confiscate or destroy the animals, or prevent the     <font color="blue">utilization</font> of their milk</td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">government</font>al actions <font color="blue">would prevent</font>     the use of the <font color="blue">recombinant</font> proteins</td>
    </tr>
    <tr>
      <td>To our knowledge, Pharming BV is the only other entity to have completed     human  clinical  trials of a <font color="blue">transgenically</font> produced product, although     Pharming has not filed for <font color="blue">marketing <font color="blue">authorization</font></font> in the <font color="blue"><font color="blue">United States</font> </font>or     Europe  for any <font color="blue"><font color="blue">therapeutic</font> protein</font> produced in the milk of transgenic     animals</td>
    </tr>
    <tr>
      <td>Until we have completed our <font color="blue">current pivotal trial</font> and submitted a     Biologics License Application, or BLA, to the FDA for ATryn^®, or our MAA     for ATryn^® is approved upon successful re-examination in Europe, we will     not have <font color="blue">confirmation</font> that our ATryn^® trials are sufficient for approval in     the <font color="blue"><font color="blue">United States</font> </font>or Europe</td>
    </tr>
    <tr>
      <td>If we are unable to complete all clinical     trials that may be required by the FDA or EMEA, or if any of our other     <font color="blue">transgenically</font> produced proteins in <font color="blue">development</font> are not proved to be safe or     <font color="blue">effective</font> to the <font color="blue">satisfaction</font> of <font color="blue">regulatory</font> authorities, it would have a     material adverse effect on our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, it is     possible that research and <font color="blue">discoveries by others could</font> render our transgenic     <font color="blue">technology</font>  obsolete  or  non<font color="blue">competitive</font> as a method of production for     protein-based <font color="blue">therapeutic</font> products</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font></font> for our <font color="blue">current revenue</font></td>
    </tr>
    <tr>
      <td>Our revenues and business <font color="blue">strategy depend largely on</font> our <font color="blue">entering into</font>     <font color="blue">additional</font> <font color="blue">development</font> and <font color="blue">marketing <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">third parties</font> as well</font>     <font color="blue">as existing <font color="blue"><font color="blue">agreement</font>s</font></font> for our own <font color="blue"><font color="blue">therapeutic</font> compounds</font></td>
    </tr>
    <tr>
      <td>We may not be able     to establish these <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> on <font color="blue">commercially</font></font> acceptable terms, if at all,     <font color="blue">depending on</font> the <font color="blue">market position</font> of our <font color="blue">technology</font> and our compounds</td>
    </tr>
    <tr>
      <td>The     <font color="blue">willingness</font> of potential <font color="blue">collaborators</font> to <font color="blue">enter into <font color="blue"><font color="blue">agreement</font>s</font> with us</font>     depends  on  factors  such  as the perceived <font color="blue">technological</font> or economic     <font color="blue">advantages</font> of <font color="blue">transgenic production</font> and our ability to structure a mutually     acceptable <font color="blue"><font color="blue">collaboration</font> arrangement</font></td>
    </tr>
    <tr>
      <td>For existing and future <font color="blue">development</font>     <font color="blue"><font color="blue">agreement</font>s</font>, the <font color="blue"><font color="blue"><font color="blue">collaboration</font>s</font> <font color="blue">may ultimately</font></font> be <font color="blue">unsuccessful</font>, our partners     could  terminate  the <font color="blue"><font color="blue">agreement</font>s</font> or the <font color="blue"><font color="blue">agreement</font>s</font> could expire before     meaningful <font color="blue">development</font>al milestones are reached</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the terms of     any <font color="blue">future <font color="blue"><font color="blue">collaboration</font>s</font></font>, our role in the <font color="blue"><font color="blue">collaboration</font> will often</font> be     limited to the <font color="blue">production aspects</font> of the proteins</td>
    </tr>
    <tr>
      <td>As a result, we may also     be <font color="blue">dependent</font> on <font color="blue">collaborators</font> for other aspects of the <font color="blue">development</font> of any     <font color="blue">transgenically</font> produced product, including preclinical and <font color="blue">clinical testing</font>     and <font color="blue">regulatory</font> approval, and marketing and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>The majority of our <font color="blue"><font color="blue">collaboration</font>s</font> to date have <font color="blue">been external programs</font> that     involve  proteins  <font color="blue">proprietary</font> to our partners</td>
    </tr>
    <tr>
      <td>Much of the continuing     revenue, if any, that we may receive under these <font color="blue"><font color="blue">collaboration</font>s</font> will depend     upon our partners’ <font color="blue">willingness</font> and ability to <font color="blue">successfully</font> develop and     <font color="blue">commercially</font> introduce, market and sell the version of the collaborator’s     <font color="blue">product derived from</font> our <font color="blue">transgenic production</font> systems</td>
    </tr>
    <tr>
      <td>Our <font color="blue">partners may</font>     choose <font color="blue">competitive</font> production <font color="blue">technologies</font> or <font color="blue">competitive</font> products outside     of their <font color="blue"><font color="blue">collaboration</font>s</font> with us, which could have a material adverse effect     on our business</td>
    </tr>
    <tr>
      <td>The failure of any <font color="blue">significant</font> number of these external     <font color="blue"><font color="blue">collaboration</font>s</font> could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>If  <font color="blue">clinical trials</font> of any of our <font color="blue">transgenically</font> produced products are     <font color="blue">unsuccessful</font>  or  delayed,  we would be unable to meet our anticipated     <font color="blue">development</font> timeline, which could cause our stock price to decline</td>
    </tr>
    <tr>
      <td>We and our <font color="blue">collaborators</font> must <font color="blue">demonstrate</font> through preclinical and clinical     trials that our <font color="blue">transgenically</font> produced products are safe and <font color="blue">effective</font> for     use in humans</td>
    </tr>
    <tr>
      <td>Clinical trials are expensive and may take <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>Several <font color="blue">factors could</font> prevent or <font color="blue">delay completion</font> of these trials, including     an  <font color="blue">inability</font> to enroll the required number of patients or <font color="blue">demonstrate</font>     <font color="blue">adequately</font> the safety or efficacy of the product for humans</td>
    </tr>
    <tr>
      <td>If safety     concerns develop, <font color="blue">regulatory</font> authorities could stop or delay our trials</td>
    </tr>
    <tr>
      <td>Furthermore, the results from early <font color="blue">clinical trials</font> are often not predictive     of results in later <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>Any <font color="blue">transgenically</font> produced products for which we obtain <font color="blue">regulatory</font> approval     will be subject to <font color="blue">continuing review</font> and extensive <font color="blue">regulatory</font> <font color="blue">requirements</font>,     which <font color="blue">could affect</font> their <font color="blue">manufacture</font> and marketing</td>
    </tr>
    <tr>
      <td>If  and  when  the  FDA  or  other foreign agencies approve any of our     <font color="blue">transgenically</font> produced products under <font color="blue">development</font>, the <font color="blue">manufacture</font> and     marketing of these <font color="blue">products will</font> be subject to <font color="blue">continuing regulation</font> and     <font color="blue">product approvals may</font> be withdrawn if problems occur after <font color="blue">initial approval</font></td>
    </tr>
    <tr>
      <td>Post-approval regulation includes <font color="blue"><font color="blue">compliance with</font> current</font> Quality Systems     Regulations and Good Manufacturing Practices, known as QSR/GMP, adverse     event reporting <font color="blue">requirements</font> and <font color="blue">prohibitions on promoting</font> a product for     <font color="blue">unapproved uses</font></td>
    </tr>
    <tr>
      <td>We will also be required to obtain <font color="blue">additional</font> approvals for     any <font color="blue">significant</font> alterations in the product’s labeling or <font color="blue">manufacturing</font>     process</td>
    </tr>
    <tr>
      <td><font color="blue">Enforcement </font>actions resulting <font color="blue">from failure</font> to <font color="blue">comply with</font> QSR/GMP     <font color="blue">requirements</font> could result in fines, suspensions of approvals, recalls of     products, operating <font color="blue">restrictions</font> and <font color="blue">criminal prosecution</font>s, and affect the     <font color="blue">manufacture</font> and marketing of our <font color="blue">transgenically</font> produced products</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>or other <font color="blue">regulatory</font> agencies could withdraw a <font color="blue"><font color="blue">previously</font> approved product</font>     from the <font color="blue">market upon receipt</font> of <font color="blue">newly discovered</font> information, including a     failure  to  <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> and the occurrence of     <font color="blue">unanticipated</font>  <font color="blue">problems with products following approval</font></td>
    </tr>
    <tr>
      <td>Any of these     <font color="blue">withdrawals</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our operating results</td>
    </tr>
    <tr>
      <td>We  have  limited <font color="blue">manufacturing</font> <font color="blue">capability</font> and <font color="blue">may rely on third party</font>     contract <font color="blue">manufacture</font>rs to purify and formulate our <font color="blue">transgenically</font> produced     products</td>
    </tr>
    <tr>
      <td>We have the <font color="blue">capability</font> to purify pre-clinical and <font color="blue">clinical trial quantities</font>     of our <font color="blue">transgenically</font> produced products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">current capacity allows us</font> to     purify products for <font color="blue">clinical trials</font>, up to and including <font color="blue">Phase II We </font>also     rely upon third party <font color="blue">manufacture</font>rs to purify and formulate <font color="blue">significant</font>     pre-clinical, clinical and <font color="blue">commercial quantities</font> of our <font color="blue">transgenically</font>     produced products</td>
    </tr>
    <tr>
      <td>We <font color="blue">will depend on</font> these third party <font color="blue">manufacture</font>rs to     perform  their  <font color="blue">obligations</font>  in a <font color="blue">timely manner</font> and in <font color="blue">accordance with</font>     applicable <font color="blue">government</font> <font color="blue">regulations</font> in order to conduct our <font color="blue">clinical trials</font> or     <font color="blue">commercialize</font> any of our products</td>
    </tr>
    <tr>
      <td>In addition, there are very few third     party <font color="blue">manufacture</font>rs that have <font color="blue">sufficient production capacity</font> to <font color="blue">manufacture</font>     all of our <font color="blue">products either</font> for our <font color="blue">clinical trials</font> or on a <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>Our third party <font color="blue">manufacture</font>rs may encounter <font color="blue"><font color="blue">difficult</font>ies</font>, including problems     involving:           •   <font color="blue">in<font color="blue">consistent</font> production yields</font>;           •   <font color="blue">poor quality control</font> and assurance or inadequate <font color="blue">process controls</font>;           •   lack of <font color="blue">compliance with</font> FDA, EMEA and other <font color="blue">regulations</font>; and           •   <font color="blue">high production costs</font></td>
    </tr>
    <tr>
      <td>These contract <font color="blue">manufacture</font>rs may not be able to <font color="blue">manufacture</font> our <font color="blue">products at</font>     a cost or in <font color="blue">quantities <font color="blue">necessary</font></font> to make them <font color="blue"><font color="blue">commercially</font> viable</font></td>
    </tr>
    <tr>
      <td>If we     are  unable  to enter into <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">additional</font> <font color="blue">manufacture</font>rs on     <font color="blue"><font color="blue">commercially</font> reasonable terms</font>, or if there is <font color="blue">poor performance on</font> the part     of our third party <font color="blue">manufacture</font>rs, we may not be able to complete <font color="blue">development</font>     of, or market, our <font color="blue">transgenically</font> produced products</td>
    </tr>
    <tr>
      <td>We  have  <font color="blue">contracts with</font> Cambrex Bio Science Hopkinton for large scale     <font color="blue">purification</font> and with Medimmune (Holland) for fill/finish services of our     lead product, ATryn^®</td>
    </tr>
    <tr>
      <td>Although we have identified     <font color="blue">possible alternative suppliers <font color="blue">with respect</font></font> to these services for this     product, interruptions in these services and the process of changing to an     alternative <font color="blue">manufacture</font>r could have a material adverse effect on our timely     ability  to  <font color="blue">manufacture</font>  <font color="blue">bulk delivery</font> of ATryn^® for delivery to our     <font color="blue">collaborators</font> or to market <font color="blue">distribution</font> after <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td><font color="blue">Transgenically </font>produced <font color="blue">products may</font> never become <font color="blue">commercially</font> successful</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">transgenically</font> produced products are <font color="blue">successfully</font> developed and     <font color="blue">approved by</font> the FDA and foreign <font color="blue">regulatory</font> agencies, they may not enjoy     commercial <font color="blue">acceptance</font> or success, which would <font color="blue"><font color="blue">adversely</font> affect</font> our business     and  results  of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Several <font color="blue">factors could</font> limit our success,     including:           •   limited market <font color="blue">acceptance</font> among patients, physicians, <font color="blue">medical centers</font>     and <font color="blue">third party payors</font>;           •   our <font color="blue">inability</font> to access a <font color="blue">sales force capable</font> of marketing the     product, either through a <font color="blue">third party contract sales force</font> or by     <font color="blue">establishing</font> our own <font color="blue">internal sales force</font>;                                           14     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font>  •   our <font color="blue">inability</font> to supply a <font color="blue">sufficient amount</font> of product to <font color="blue">meet market</font>     demand;           •   the number and <font color="blue">relative efficacy</font> of <font color="blue">competitive</font> products that may     <font color="blue">subsequently enter</font> the market; and           •   for a <font color="blue">transgenically</font> produced <font color="blue">product designed</font> to replace or     supplement currently marketed non-<font color="blue">transgenically</font> produced products, the     relative risk-benefit profile and cost-<font color="blue">effective</font>ness of the <font color="blue">transgenically</font>     produced product</td>
    </tr>
    <tr>
      <td>In addition, it is possible that we or our <font color="blue">collaborative partners will</font> be     <font color="blue">unsuccessful</font> in developing, marketing or <font color="blue">implementing</font> a <font color="blue">commercialization</font>     strategy for any <font color="blue">transgenically</font> produced products</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">may fail due</font> to <font color="blue">intense <font color="blue">competition</font></font> in our industry</td>
    </tr>
    <tr>
      <td>The industry in which we operate is highly <font color="blue">competitive</font> and <font color="blue">may become even</font>     more so</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> have greater financial and human resources     and more experience in research and <font color="blue">development</font> than we have</td>
    </tr>
    <tr>
      <td>We will need     to  continue to devote substantial efforts and expense in research and     <font color="blue">development</font> to maintain a <font color="blue">competitive</font> position for our <font color="blue">transgenic production</font>     <font color="blue">technology</font> and <font color="blue">potential product offerings</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that others     will develop <font color="blue">alternative <font color="blue">technologies</font></font> or products that will render our     <font color="blue">proposed products</font> or <font color="blue"><font color="blue">technologies</font> obsolete</font></td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue">significant</font>     <font color="blue">competition</font> for our protein <font color="blue">development</font> and <font color="blue">production capabilities from</font>     other  companies</td>
    </tr>
    <tr>
      <td>In  addition,  our  potential <font color="blue">transgenic production</font>     capabilities may face <font color="blue">significant</font> <font color="blue">competition</font> from <font color="blue">biological products</font>     <font color="blue">manufacture</font>d in <font color="blue">cell culture</font> or by other <font color="blue">traditional protein production</font>     methods</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">will also compete against</font> other <font color="blue">companies whose</font>     business is dedicated to offering <font color="blue">transgenic production</font> and <font color="blue">with prospective</font>     customers or <font color="blue">collaborators</font> who decide to pursue such <font color="blue">transgenic production</font>     <font color="blue">internally</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>that complete <font color="blue">clinical trials</font>, obtain <font color="blue">regulatory</font>     approvals and <font color="blue">begin <font color="blue">commercial sale</font>s</font> of their products before <font color="blue">us will enjoy</font>     a  <font color="blue">significant</font>  <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>We anticipate that we will face     increased <font color="blue">competition</font> in the <font color="blue">future as new companies enter</font> the market and     <font color="blue">alternative <font color="blue">technologies</font></font> become available</td>
    </tr>
    <tr>
      <td>For  ATryn^®, a number of companies <font color="blue">internationally</font> produce and market     <font color="blue">antithrombin</font> from the <font color="blue">fractionation</font> of <font color="blue">human plasma</font></td>
    </tr>
    <tr>
      <td>CSL has <font color="blue">approximately</font> a     40prca share of this market worldwide, but is not approved for sale in the US     Talecris Bio<font color="blue">therapeutic</font>s, <font color="blue">which purchased</font> Bayer’s plasma business, is the     <font color="blue">only company</font> that has <font color="blue">commercially</font> available fractionated <font color="blue">antithrombin</font>     material that is approved for sale in the US, <font color="blue">which sales represent only</font>     about 1prca of the <font color="blue">worldwide market</font></td>
    </tr>
    <tr>
      <td><font color="blue">The European </font>market is <font color="blue">served by multiple</font>     products, none of which is <font color="blue">approved throughout</font> the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>products are <font color="blue">fractionated from <font color="blue">human plasma</font> by</font> Octapharma, CSL Limited,     Grifols, Kedrian, Baxter International, LFB and BioProducts Laboratory</td>
    </tr>
    <tr>
      <td>Like  <font color="blue">antithrombin</font>,  alpha-1  <font color="blue">antitrypsin</font> is <font color="blue">sold today as</font> a result of     <font color="blue">fractionation</font> of <font color="blue">human plasma</font></td>
    </tr>
    <tr>
      <td>Talecris has a <font color="blue">significant</font> presence in the     US with a <font color="blue">product called</font> Prolastin^®</td>
    </tr>
    <tr>
      <td>This product is approved for chronic     use in <font color="blue">patients with</font> a genetic <font color="blue">deficiency</font> of alpha-1 <font color="blue">antitrypsin</font> who are     prone to <font color="blue">pulmonary disorders such as emphasyma</font></td>
    </tr>
    <tr>
      <td>There are a number of <font color="blue">companies worldwide</font> that produce and <font color="blue">market human</font>     <font color="blue">serum albumin from</font> the <font color="blue">fractionation</font> of <font color="blue">human plasma</font>, including Talecris     BioTherapeutics, CSL Limited and Baxter International</td>
    </tr>
    <tr>
      <td>We are aware of two     <font color="blue">companies worldwide</font> that are developing <font color="blue">recombinant</font> forms of <font color="blue">human serum</font>     <font color="blue">albumin derived from yeast cultures</font></td>
    </tr>
    <tr>
      <td>One company, Aventis, is developing its     <font color="blue">recombinant</font> albumin product for the <font color="blue">excipient market</font></td>
    </tr>
    <tr>
      <td>The other lead company     is <font color="blue">Mitsubishi Pharma Corporation </font>which has <font color="blue">been active</font> in developing human     <font color="blue">albumin through genetic manipulation</font> of Pichia pastoris, or yeast, on a     <font color="blue">commercial scale</font> for use in Japan and other parts of Asia</td>
    </tr>
    <tr>
      <td>To the extent     that a market develops for <font color="blue">transgenic production</font> of <font color="blue"><font color="blue">therapeutic</font> compounds</font>     <font color="blue">generally</font>, similar to the market for cell-based production of <font color="blue">therapeutic</font>     compounds,  we  may be in <font color="blue">competition</font> with other transgenic <font color="blue">technology</font>     companies</td>
    </tr>
    <tr>
      <td><font color="blue">Pharming  </font>Group NV and BioProtein Technologies are other     <font color="blue">companies known</font> to us that are <font color="blue">extensively</font> engaged in the <font color="blue">application</font> of     transgenic  <font color="blue">technology</font>  in  mammals for the production of proteins for     <font color="blue">therapeutic</font> use in humans</td>
    </tr>
    <tr>
      <td>Pharming, based in the Netherlands, is primarily     engaged in the <font color="blue">development</font> of <font color="blue">recombinant</font> proteins in the milk of transgenic     cows and rabbits</td>
    </tr>
    <tr>
      <td>Pharming reports that it has one product in clinical     <font color="blue">development</font> that has completed <font color="blue">Phase III </font>studies in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pharming  </font>has  also  submitted a request to the FDA to recognize their     <font color="blue">lactoferrin</font>  product  as  <font color="blue">generally</font>  regarded  as safe for nutritional     <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>BioProtein  Technologies  is  a  contract <font color="blue">manufacturing</font>     <font color="blue">organization specializing</font> in the production of human <font color="blue"><font color="blue">therapeutic</font> protein</font>s     and vaccines in the milk of <font color="blue">transgenic rabbits also under</font> a <font color="blue">technology</font>     license  <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>There are also other <font color="blue">companies seeking</font> to develop     transgenic <font color="blue">technology</font> in animals and in plants, which may be <font color="blue">competitive</font>     with our <font color="blue">technology</font> <font color="blue">with respect</font> to our patents and <font color="blue">proprietary</font> rights as     <font color="blue">discussed further</font> below</td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>We <font color="blue">may face public concerns about <font color="blue">genetic engineering</font></font> in animals</td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font> involve <font color="blue">genetic engineering</font> in animals</td>
    </tr>
    <tr>
      <td>The success of our     potential commercial <font color="blue">products will</font> depend in part on public <font color="blue">acceptance</font> of     the use of <font color="blue">genetic engineering</font></td>
    </tr>
    <tr>
      <td>Public <font color="blue">attitudes may</font> be <font color="blue">influenced by</font> claims     that these types of <font color="blue">activities</font> are unsafe and our <font color="blue">products may</font> not gain the     <font color="blue">acceptance</font> of the public or the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Negative <font color="blue">public reaction</font>     to  genetic  engineering <font color="blue">activities</font> in <font color="blue">general could</font> result in greater     <font color="blue">restrictive <font color="blue">legislation</font></font> and <font color="blue">regulations</font> involving nuclear transfer and other     <font color="blue">methodologies</font>  which  <font color="blue">could impede</font> our ability to conduct our business     efficiently, delay preclinical studies or future <font color="blue">clinical trials</font>, or prevent     us or our <font color="blue">partners from</font> obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font> or <font color="blue">commercializing</font>     <font color="blue">transgenically</font> produced products</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on patents</font> and <font color="blue">proprietary</font> rights that may fail to protect our     business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will partly depend on</font> our ability to obtain and maintain patent     or other <font color="blue">proprietary</font> protection for our <font color="blue">technologies</font>, products and processes     such as:           •   <font color="blue">compositions</font> of matter or processes;           •   processes developed by our employees; or           •   uses of <font color="blue">compositions</font> of matter <font color="blue">discovered through</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain the <font color="blue">necessary</font> <font color="blue">proprietary</font> protection</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">success will also depend on</font> our ability to operate <font color="blue">without infringing</font> the     <font color="blue">proprietary</font>  rights  of other parties</td>
    </tr>
    <tr>
      <td>Legal standards relating to the     validity of patents covering <font color="blue">pharmaceutical</font> and bio<font color="blue">technological</font> inventions     and the scope of claims made under these patents are still developing</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>is  no  <font color="blue">consistent</font>  policy  regarding the breadth of claims allowed in     bio<font color="blue">technology</font> patents</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of a bio<font color="blue">technology</font> company is     susceptible to <font color="blue">uncertainty</font> and <font color="blue">involves complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>Our patents <font color="blue">generally</font> expire between 2013 and 2015, with the     exception being the <font color="blue">recent allowance</font> in the <font color="blue"><font color="blue">United States</font> </font>of a <font color="blue">patent which</font>,     after <font color="blue">issuance would</font> expire in 2021</td>
    </tr>
    <tr>
      <td>This <font color="blue">patent provides us with</font> claim     coverage for the production of <font color="blue"><font color="blue">therapeutic</font> protein</font>s in the <font color="blue">mammary gland</font>s of     <font color="blue">transgenic mammals</font> and is expected to issue by the middle of 2006</td>
    </tr>
    <tr>
      <td>One     in-licensed European patent, pertaining to <font color="blue"><font color="blue">transgenic animals</font> secreting</font>     proteins in milk, expires in 2006</td>
    </tr>
    <tr>
      <td>In <font color="blue">accordance with</font> ongoing research and     <font color="blue">development</font> efforts, we have 61 pending US patent <font color="blue">application</font>s and 226     corresponding foreign <font color="blue">application</font>s covering relevant and newly developed     portions of our transgenic <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Several of these pending <font color="blue">application</font>s     are included in various cross-licensing or out-licensing <font color="blue">arrangements</font> with     other  companies  that  in  turn  provide  access to their <font color="blue">proprietary</font>     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Specifically </font>we have cross-licensed our <font color="blue">proprietary</font> <font color="blue">technology</font>     for the production of proteins in milk to <font color="blue">Pharming BV Other </font><font color="blue">technologies</font>     for which we hold <font color="blue">existing patents</font> include: protein <font color="blue">purification</font> from the     milk of <font color="blue">transgenic animals</font>, the production of monoclonal and assembled     <font color="blue">antibodies at commercial levels</font> in the milk of <font color="blue">transgenic mammals</font>, the     production of <font color="blue">recombinant</font> <font color="blue">antithrombin</font> in the milk of <font color="blue">transgenic goats</font> and     <font color="blue">one covering</font> the production of <font color="blue">Prolactin </font>in the milk of <font color="blue">transgenic animals</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that we will receive <font color="blue">issued patents based on pending</font> or     future <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue">issued patents may</font> not contain claims <font color="blue">sufficiently</font>     broad  to  protect  us  against  <font color="blue">competitors</font>  with similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Additionally, our patents, our partners’ patents and patents for which we     have  license  rights  may  be  challenged,  narrowed,  invalidated or     <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">rights granted under patents may</font> not <font color="blue">provide us</font>     with any <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>We may have to <font color="blue">initiate arbitration</font> or <font color="blue">litigation</font> to enforce our patent and     <font color="blue">license rights</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> file patent <font color="blue">application</font>s that claim     <font color="blue">technology</font> also claimed by us, we may have to <font color="blue">participate</font> in <font color="blue">interference</font> or     <font color="blue">opposition proceedings</font> to determine the priority of invention</td>
    </tr>
    <tr>
      <td>An adverse     <font color="blue">outcome could</font> subject us to <font color="blue">significant</font> <font color="blue">liabilities</font> to <font color="blue">third parties</font> and     require us to <font color="blue">cease using</font> the <font color="blue">technology</font> or to license the <font color="blue">disputed rights</font>     from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain any required <font color="blue">licenses on</font>     <font color="blue">commercially</font> acceptable terms or at all</td>
    </tr>
    <tr>
      <td>The cost to us of any <font color="blue">litigation</font> or proceeding relating to <font color="blue">patent rights</font>,     even if resolved in our favor, could be substantial</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font>     may  be  able  to  sustain the costs of complex patent <font color="blue">litigation</font> more     <font color="blue"><font color="blue">effective</font>ly</font> than we can because of their <font color="blue">substantially</font> greater resources</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from the <font color="blue">initiation</font> and <font color="blue">continuation</font> of any pending     patent or related <font color="blue">litigation</font> could have a material adverse effect on our     ability to compete in the marketplace</td>
    </tr>
    <tr>
      <td>Advanced Cell Technologies, Inc, or     ACT, has announced that the <font color="blue">Board of Patent Appeals and Interferences </font>of the     <font color="blue">US Patent Office </font>has entered a judgment in an <font color="blue">interference</font> proceeding in     favor of a patent <font color="blue">application</font> of <font color="blue">Geron Corporation </font>against ACT on all counts     as to the priority of ACT’s US Patent Nodtta 5cmam945cmam577, which we <font color="blue">license from</font>     ACT ACT has appealed that decision                                           16     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>in a proceeding in US District Court, <font color="blue">during which proceeding</font> we believe     that we <font color="blue">may continue</font> to rely on the validity of the <font color="blue">disputed patent</font></td>
    </tr>
    <tr>
      <td><font color="blue">Until     </font>the final resolution of this dispute, <font color="blue">the Geron </font><font color="blue">application</font> will not affect     our freedom to operate <font color="blue">with respect</font> to the claims involved in the dispute</td>
    </tr>
    <tr>
      <td>If the proceeding is ultimately resolved in favor of Geron, this could     <font color="blue"><font color="blue">adversely</font> affect</font> our ability to <font color="blue">conduct nuclear transfer</font> after the date of     <font color="blue">such determination</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">also licensed certain nuclear transfer</font>     <font color="blue">technology</font> from Pharming and Tufts University, we do not know at this time     what impact, if any, this <font color="blue">proceeding involving</font> ACT <font color="blue">may ultimately</font> have on     our ability to <font color="blue">practice nuclear transfer</font> for the production of animals     expressing  <font color="blue"><font color="blue">therapeutic</font> protein</font>s in their milk</td>
    </tr>
    <tr>
      <td>Neither ATryn^^®^, our     principal product, nor rhAAT have been produced <font color="blue">using nuclear transfer</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We rely on certain <font color="blue">proprietary</font> trade secrets and know-how that are not     patentable</td>
    </tr>
    <tr>
      <td>We have <font color="blue">taken measures</font> to protect our <font color="blue">unpatented trade secrets</font>     and  know-how,  including  having  our employees, consultants and some     <font color="blue">contractors</font> execute confidentiality <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> could be     breached</td>
    </tr>
    <tr>
      <td>If so, it is possible that our remedies for a <font color="blue">given breach might</font>     be  inadequate</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that <font color="blue">competitors</font> emerge who could     in<font color="blue">dependent</font>ly  develop or discover our trade secrets or that the trade     <font color="blue">secrets could otherwise become known</font></td>
    </tr>
    <tr>
      <td>Recovery from any <font color="blue">catastrophic event may</font> not be adequate</td>
    </tr>
    <tr>
      <td>While we have measures in place to minimize and recover from catastrophic     events that may <font color="blue">substantially</font> destroy our animal herd(s), these <font color="blue">measures may</font>     not  be adequate to recover our <font color="blue">production processes quickly enough</font> to     support critical timelines, collaborator needs or <font color="blue">market demands</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">catastrophic events may</font> include <font color="blue">animal diseases</font> that breach our <font color="blue">biosecurity</font>     measures or weather events such as tornadoes, earthquakes or fires</td>
    </tr>
    <tr>
      <td>In     addition, these <font color="blue">catastrophic events may</font> render some or all of the products     at the <font color="blue">affected facilities unusable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successful  </font><font color="blue">commercialization</font> of our <font color="blue">products will</font> depend on obtaining     coverage and <font color="blue">reimbursement</font> for use of the products from third-party payors</td>
    </tr>
    <tr>
      <td>Sales of <font color="blue">pharmaceutical</font> products depend largely on the <font color="blue">reimbursement</font> of     patients’ medical expenses by <font color="blue">government</font> <font color="blue">health care</font> programs and private     health insurers</td>
    </tr>
    <tr>
      <td>It is possible that <font color="blue">third party payors</font> will not reimburse     sales of our <font color="blue">transgenically</font> produced products</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font><font color="blue">by third party</font>     <font color="blue">payors depends on</font> a number of factors, including the payor’s determination     that  use  of  the  product is safe and <font color="blue">effective</font>, not <font color="blue">experimental</font> or     investigational, medically <font color="blue">necessary</font>, <font color="blue">appropriate</font> for the <font color="blue">specific patient</font>     and cost-<font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>in the <font color="blue"><font color="blue">United States</font> </font>or foreign countries     may not be available or maintained for any of our products</td>
    </tr>
    <tr>
      <td>If we do not     obtain approvals for adequate third party <font color="blue">reimbursement</font>s, we may not be able     to establish or maintain <font color="blue">price levels sufficient</font> to realize an <font color="blue">appropriate</font>     return on our or our partners’ investment in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Any limits     on <font color="blue">reimbursement</font> available from <font color="blue">third party payors</font> may reduce the demand     for, or <font color="blue"><font color="blue">negatively</font> affect</font> the price of, our or our partners’ products</td>
    </tr>
    <tr>
      <td>Without the financial support of the <font color="blue">government</font> or <font color="blue">third party insurers</font>, the     market for <font color="blue">transgenically</font> produced <font color="blue">products will</font> be limited</td>
    </tr>
    <tr>
      <td>The US federal <font color="blue">government</font> and <font color="blue">private insurers</font> are <font color="blue">continually</font> working on     ways to contain <font color="blue">health care</font> costs, particularly by limiting both coverage     and the level of <font color="blue">reimbursement</font> for new <font color="blue">therapeutic</font> products</td>
    </tr>
    <tr>
      <td>The <font color="blue">government</font>     or  private  insurers  may  institute  <font color="blue">future price controls</font> and other     cost-containment  <font color="blue">measures on</font> Medicare, Medicaid and other <font color="blue">health care</font>     <font color="blue">insurance spending</font></td>
    </tr>
    <tr>
      <td>These controls and limits <font color="blue">could affect</font> the payments we     <font color="blue">collect from sales</font> of our products</td>
    </tr>
    <tr>
      <td>Internationally, medical <font color="blue">reimbursement</font>     systems vary <font color="blue">significant</font>ly, with some <font color="blue">medical centers</font> having fixed budgets,     <font color="blue">regardless</font> of levels of <font color="blue">patient treatment</font>, and other countries requiring     <font color="blue">application</font> for, and approval of, <font color="blue">government</font> or third party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Even if we or our partners succeed in bringing <font color="blue">transgenically</font> produced     products to market, uncertainties regarding future <font color="blue">health care</font> policy,     <font color="blue">legislation</font> and regulation, as well as private market practices, could     affect  our  ability  to  sell our products in <font color="blue">commercially</font> acceptable     <font color="blue">quantities at profitable prices</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">negotiate with</font> <font color="blue">potential market</font>ing <font color="blue">partners may</font> be limited</td>
    </tr>
    <tr>
      <td>If we choose to <font color="blue">commercialize</font> ATryn^® with an <font color="blue">additional</font> marketing partner     outside  of  Asia, <font color="blue">Genzyme Corporation </font>has an <font color="blue">exclusive first</font> right of     <font color="blue">negotiation</font> for <font color="blue">commercialization</font> rights</td>
    </tr>
    <tr>
      <td>This right is <font color="blue">triggered on</font> an     <font color="blue">indication</font>-by-<font color="blue">indication</font>  <font color="blue">basis at such</font> time as we apply for marketing     <font color="blue">approval with</font> a <font color="blue">regulatory</font> authority</td>
    </tr>
    <tr>
      <td>This right does not apply if we have     <font color="blue">already entered into</font> a <font color="blue">collaboration</font> or other <font color="blue"><font color="blue">agreement</font> with</font> a prospective     research,  <font color="blue">development</font>  and <font color="blue">marketing partner prior</font> to such <font color="blue">regulatory</font>     submission</td>
    </tr>
    <tr>
      <td>For example, the right also does not apply to <font color="blue">commercialization</font>     rights in Europe, Canada or the Middle East for any <font color="blue">indication</font> because those     rights are subject to our licensing and supply <font color="blue">agreement</font> entered into with     <font color="blue">LEO Pharma in October </font>2005</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>The <font color="blue">manufacture</font> and sale of our <font color="blue">products may</font> expose us to <font color="blue">product <font color="blue">liability</font></font>     claims for which we could have substantial <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We face an inherent risk of <font color="blue">product <font color="blue">liability</font></font> exposure related to testing of     our <font color="blue">transgenically</font> produced products in human <font color="blue">clinical trials</font> and will face     <font color="blue">even greater risks</font> when we <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>An individual may     bring a <font color="blue">product <font color="blue">liability</font></font> claim <font color="blue">against us</font> if one of our products causes, or     is  claimed to have caused, an injury or is found to be unsuitable for     consumer  use,  even  if  the  product  involved is granted <font color="blue">regulatory</font>     <font color="blue">authorization</font> for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>We do not maintain <font color="blue">product <font color="blue">liability</font></font>     insurance, although we do have <font color="blue">product <font color="blue">liability</font></font> insurance in place for the     <font color="blue">clinical trials</font> conducted to support our <font color="blue">Marketing Authorization Application     </font>for filing with <font color="blue">the EMEA </font>for our ATryn^® <font color="blue">program under</font> an <font color="blue">insurance policy</font>     <font color="blue">arrangement with</font> <font color="blue">Genzyme Corporation </font>and we have obtained <font color="blue">product <font color="blue">liability</font></font>     coverage for the <font color="blue">clinical trials</font> to be conducted to support a filing for     <font color="blue">marketing approval</font> of ATryn^^®^ with the FDA through our own policies</td>
    </tr>
    <tr>
      <td>It is     possible that our <font color="blue"><font color="blue">insurance coverage</font> will</font> not be sufficient to cover any     claim</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product <font color="blue">liability</font></font> claim brought <font color="blue">against us</font>, with or without     merit, could result in:           •   <font color="blue">liabilities</font> that <font color="blue">substantially</font> exceed our <font color="blue">product <font color="blue">liability</font></font> insurance,     which we would then be required to pay from other sources, if available;           •   an increase of our <font color="blue">product <font color="blue">liability</font></font> insurance rates or the <font color="blue">inability</font>     to maintain <font color="blue">insurance coverage</font> in the future on acceptable terms or at all;           •   damage to our reputation and the reputation of our products, resulting     in <font color="blue">lower sales</font>;           •   <font color="blue">regulatory</font> investigations that could require <font color="blue">costly recalls</font> or product     <font color="blue">modifications</font>; and           •   the diversion of <font color="blue">management</font>’s attention from managing our business</td>
    </tr>
    <tr>
      <td>Qualified managerial and <font color="blue">scientific personnel</font> are scarce in our industry</td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent</font> on the <font color="blue">principal members</font> of our scientific and     <font color="blue">management</font>  staff</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">success will depend</font> in part on our ability to     identify, attract and retain <font color="blue">qualified managerial</font> and <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>There is <font color="blue">intense <font color="blue">competition</font></font> for <font color="blue">qualified personnel</font> in our industry</td>
    </tr>
    <tr>
      <td>We may     not be able to continue to attract and retain <font color="blue">personnel with</font> the advanced     technical  <font color="blue">qualifications</font>  or  managerial  <font color="blue">expertise <font color="blue">necessary</font></font> for the     <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>If we fail to attract and retain <font color="blue">key personnel</font>,     it could have a material adverse effect on our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have employment <font color="blue"><font color="blue">agreement</font>s</font> with our executive     officers,  but these <font color="blue"><font color="blue">agreement</font>s</font> do not guarantee that they will remain     employed  with us in the future</td>
    </tr>
    <tr>
      <td>If we lose an <font color="blue">executive officer</font>, or a     <font color="blue">significant</font> number of our staff, or are unable to hire and retain qualified     personnel, then our ability to develop and <font color="blue">commercialize</font> our products and     <font color="blue">processes may</font> be delayed or impaired</td>
    </tr>
    <tr>
      <td>We do not carry <font color="blue">key man insurance</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain an <font color="blue">effective</font> system of <font color="blue">internal controls</font>, we may not     be able to <font color="blue">accurately</font> report our financial results or <font color="blue">prevent fraud</font></td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002 requires that we report annually on the     <font color="blue">effective</font>ness of our <font color="blue">internal controls</font> over financial reporting</td>
    </tr>
    <tr>
      <td>Among other     things, we must perform systems and process <font color="blue">evaluation</font> and testing</td>
    </tr>
    <tr>
      <td>We must     <font color="blue">also conduct</font> an assessment of our <font color="blue">internal controls</font> to allow <font color="blue">management</font> to     report on, and our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm to audit,     our  assessment  of our <font color="blue">internal controls</font> over financial reporting, as     required by Section 404 of the Sarbanes-Oxley Act</td>
    </tr>
    <tr>
      <td>These <font color="blue">requirements</font> were     <font color="blue">effective</font> for the first time for 2004</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> our Section 404     <font color="blue">compliance efforts</font>, we have incurred or expended, and expect to continue to     incur or expend, substantial <font color="blue">accounting</font> and other expenses and <font color="blue">significant</font>     <font color="blue">management</font>  time and resources</td>
    </tr>
    <tr>
      <td>Any <font color="blue">subsequent assessment by us</font> or our     in<font color="blue">dependent</font>  registered  public <font color="blue">accounting</font> firm may reveal <font color="blue">significant</font>     <font color="blue">deficiencies</font> or material <font color="blue">weaknesses</font> in our <font color="blue">internal controls</font>, which may need     to be disclosed in <font color="blue">subsequent periodic</font> reports <font color="blue">filed with</font> the <font color="blue">Securities </font>and     Exchange Commission, or SEC and could result in a <font color="blue">restatement</font> of <font color="blue">previously</font>     <font color="blue">issued financial</font> information</td>
    </tr>
    <tr>
      <td><font color="blue">Disclosures </font>of this type could cause investors     to lose confidence in our financial reporting and may <font color="blue"><font color="blue">negatively</font> affect</font> the     price  of  our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">effective</font> <font color="blue">internal controls</font> are     <font color="blue">necessary</font> to produce <font color="blue">reliable financial</font> reports and to <font color="blue">prevent fraud</font></td>
    </tr>
    <tr>
      <td>If we     have <font color="blue">deficiencies</font> in our <font color="blue">internal controls</font> over financial reporting, these     <font color="blue">deficiencies</font> may <font color="blue">negatively</font> impact our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________    [45]Table of <font color="blue"><font color="blue">Contents       </font>     </font>             RISKS RELATED TO OUR COMMON STOCK        We have <font color="blue">obligations</font> to <font color="blue">issue shares</font> of <font color="blue">common stock</font> in the future that will     dilute your <font color="blue">ownership interest</font> and may <font color="blue"><font color="blue">adversely</font> affect</font> our stock price</td>
    </tr>
    <tr>
      <td>Sales of substantial amounts of our <font color="blue">common stock</font> in the <font color="blue">public market</font>, or     the <font color="blue">perception</font> that <font color="blue">such sales may</font> occur, could <font color="blue"><font color="blue">adversely</font> affect</font> our common     stock’s <font color="blue">market price</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>1, 2006, there were 60cmam647cmam874 shares of     our <font color="blue">common stock</font> outstanding</td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>1, 2006, options to purchase an     aggregate of 4cmam414cmam748 shares of <font color="blue">common stock</font> at varying <font color="blue">exercise price</font>s     were outstanding; of this total, options to purchase 3cmam498cmam198 shares were     <font color="blue">immediately exercisable</font> and these <font color="blue">shares could</font> be <font color="blue">immediately resold into</font>     the <font color="blue">public market</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>1, 2006, Genzyme held 4cmam924cmam919 shares of     our <font color="blue">common stock</font> which could be sold into the <font color="blue">public market</font>s under Rule 144     of the <font color="blue">Securities </font>Act</td>
    </tr>
    <tr>
      <td>Genzyme is <font color="blue">also entitled</font> to <font color="blue">registration rights with</font>     respect to some of these shares</td>
    </tr>
    <tr>
      <td>An <font color="blue">additional</font> 373cmam324 shares of our common     stock, issuable to Genzyme <font color="blue">upon exercise</font> of <font color="blue">outstanding warrants</font>, are also     entitled to registration rights, which could expedite the resale of such     <font color="blue">shares into</font> the <font color="blue">public market</font></td>
    </tr>
    <tr>
      <td>We also have <font color="blue">outstanding warrants</font> to purchase an aggregate of 6cmam823cmam668     shares of our <font color="blue">common stock</font> at <font color="blue">exercise price</font>s ranging from dlra2dtta05 to dlra8dtta75     per share, which were issued to investors in <font color="blue">various prior financings</font></td>
    </tr>
    <tr>
      <td>The warrants to purchase an aggregate of 1cmam828cmam573 of these shares of our     <font color="blue">common stock</font>, which we issued in our August 2005 private placement, (the     “August 2005 Warrants”) had an <font color="blue">initial <font color="blue">exercise price</font></font> of dlra2dtta68 per share</td>
    </tr>
    <tr>
      <td>The <font color="blue">exercise price</font> of these warrants is subject to <font color="blue">adjustment upon</font> the     issuance of any shares of our <font color="blue">common stock</font> or <font color="blue">common stock</font> <font color="blue">equivalents</font> at an     <font color="blue">exercise price</font> lower than the then-<font color="blue">effective</font> <font color="blue">exercise price</font> per share (a     “<font color="blue">Dilutive Issuance</font>”)</td>
    </tr>
    <tr>
      <td>Upon a <font color="blue">Dilutive Issuance</font> the <font color="blue">exercise price</font> of the     unexercised portion of these <font color="blue">warrants shall</font> be <font color="blue">reduced by multiplying</font> the     then-<font color="blue">effective</font> <font color="blue">exercise price</font> by a fraction, the numerator of which is the     number  of shares of <font color="blue">common stock</font> outstanding immediately prior to the     Dilutive  Issuance plus the number of shares of <font color="blue">common stock</font> which the     <font color="blue">aggregate consideration</font> received or deemed to be received by the company in     <font color="blue">connection with</font> the <font color="blue">Dilutive Issuance</font> <font color="blue">would purchase at</font> the <font color="blue">exercise price</font>,     and the <font color="blue">denominator</font> of which is the number of shares of <font color="blue">common stock</font> and     <font color="blue">common stock</font> <font color="blue">equivalents</font> issued and <font color="blue">outstanding immediately following such</font>     <font color="blue">Dilutive Issuance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>the issuance of the shares and <font color="blue">warrants offered</font>     in the December 2005 private placement, the <font color="blue">exercise price</font> of the <font color="blue">August     </font>2005 Warrants was reduced to dlra2dtta52 per share</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue"><font color="blue">additional</font> capital</font> by issuing equity securities, the issuance     will result in a reduction of the percentage of ownership for our existing     <font color="blue"><font color="blue">shareholder</font>s</font>, a result <font color="blue">commonly referred</font> to <font color="blue">as dilution</font></td>
    </tr>
    <tr>
      <td>The extent of such     <font color="blue">dilution will vary based upon</font> the amount of <font color="blue">capital raised</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> may have a <font color="blue">volatile public <font color="blue">trading price</font></font> and low trading     volume</td>
    </tr>
    <tr>
      <td>Historically, the <font color="blue">market price</font> of our <font color="blue">common stock</font> has been highly volatile     and the market for our <font color="blue">common stock</font> has experienced <font color="blue">significant</font> price and     <font color="blue">volume fluctuations</font>, some of which are unrelated to our company’s operating     performance</td>
    </tr>
    <tr>
      <td><font color="blue">Since January </font>1, 2001, the <font color="blue">trading price</font> of our stock has     <font color="blue">fluctuated from</font> a high of dlra15dtta50 to a low of dlra0dtta61</td>
    </tr>
    <tr>
      <td>It is likely that the     <font color="blue">market price</font> of our <font color="blue">common stock</font> will continue to fluctuate in the future</td>
    </tr>
    <tr>
      <td>Factors which may have a <font color="blue">significant</font> adverse effect on our <font color="blue">common stock</font>’s     <font color="blue">market price</font> include:           •   actual or <font color="blue">potential clinical</font> or <font color="blue">regulatory</font> events relating to our     products or compounds under <font color="blue">development</font>;           •   other <font color="blue">regulatory</font> <font color="blue">development</font>s in Europe or the <font color="blue">United States</font>;           •   <font color="blue">announcements by us</font> or our <font color="blue">competitors</font> of <font color="blue">technological</font> innovations or     <font color="blue">new commercial products</font>;           •   an <font color="blue">unexpected termination</font> of one of our <font color="blue">partnerships</font>;           •   <font color="blue">development</font>s concerning our <font color="blue">proprietary</font> rights, including patent and     <font color="blue">litigation</font> matters;           •   general market <font color="blue">conditions</font>; and           •   <font color="blue">quarterly fluctuations</font> in our cash position, revenues and other     financial results</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>The <font color="blue">average daily trading volume</font> of our <font color="blue">common stock</font> for the twelve-month     period ending January 1, 2006 was <font color="blue">approximately</font> 313cmam000 shares</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our charter and by-laws and <font color="blue">Massachusetts </font>law     may result in <font color="blue">management</font> <font color="blue">entrenchment</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our stock price</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our charter, our by-laws and <font color="blue">Massachusetts </font>    <font color="blue">statutes could delay</font> or make more <font color="blue">difficult</font> a merger, tender offer or proxy     <font color="blue">contest involving us</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may delay</font> or prevent a change of     <font color="blue">control without action by</font> the <font color="blue"><font color="blue">shareholder</font>s</font>, and <font color="blue">may resist important</font> changes     <font color="blue"><font color="blue">shareholder</font>s</font> seek to make if they are <font color="blue">dissatisfied with</font> the conduct of our     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Therefore, these <font color="blue">provisions could</font> result in the <font color="blue">entrenchment</font> of     our <font color="blue">management</font> and <font color="blue"><font color="blue">adversely</font> affect</font> the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">charter grants authority</font> to the board of <font color="blue">directors</font> to <font color="blue">issue series</font> of     <font color="blue">preferred stock with <font color="blue">certain rights</font></font> and privileges, including <font color="blue">voting rights</font>,     as it deems <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">authority may enable</font> our board of <font color="blue">directors</font> to     deter or delay a change in <font color="blue">control despite</font> a shift in stock ownership, as a     result of an increase in the number of shares needed to <font color="blue">gain voting control</font></td>
    </tr>
    <tr>
      <td>This may have the effect of <font color="blue">discouraging tender offers</font> and <font color="blue">proxy contests</font>,     and give <font color="blue">management</font> the power to <font color="blue">reject certain transactions which might</font> be     desired by <font color="blue"><font color="blue">shareholder</font>s</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">provision could also</font> be deemed to benefit     incumbent <font color="blue">management</font> to the extent it <font color="blue">deters offers by persons</font> who would     wish to make changes in <font color="blue">management</font> or exercise control over <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>In addition, our by-laws may have the effect of preventing changes in our     <font color="blue">management</font> because <font color="blue"><font color="blue">shareholder</font>s</font> are required to <font color="blue">give us written</font> notice of     any proposal or <font color="blue">director nomination within</font> a <font color="blue">specified period</font> of time before     the <font color="blue">annual meeting</font> of <font color="blue"><font color="blue">shareholder</font>s</font>, certain <font color="blue">qualifications</font> for a person to     be elected to the board of <font color="blue">directors</font> must be established, and <font color="blue"><font color="blue">shareholder</font>s</font>     are <font color="blue">prohibited from calling</font> a <font color="blue">special meeting</font> of <font color="blue"><font color="blue">shareholder</font>s</font>, unless the     <font color="blue">shareholder</font> owns 90prca of our <font color="blue">outstanding voting stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">shareholder</font> rights plan is another anti-takeover device</td>
    </tr>
    <tr>
      <td>It involves a     <font color="blue">distribution</font> to our <font color="blue"><font color="blue">shareholder</font>s</font> of <font color="blue">certain rights</font> to acquire shares of our     <font color="blue">capital stock</font> in the event of an <font color="blue">acquisition</font> of a <font color="blue">predetermined</font> number of     <font color="blue">shares by</font> an investor</td>
    </tr>
    <tr>
      <td>The <font color="blue">shareholder</font> rights plan is designed to deter     <font color="blue">coercive takeover tactics</font> and to encourage a <font color="blue">party interested</font> in acquiring     the <font color="blue">corporation</font> to <font color="blue">negotiate with</font> the board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue">Massachusetts </font>corporate statutes provide anti-takeover protections</td>
    </tr>
    <tr>
      <td>Our <font color="blue">charter gives</font> effect to a provision of <font color="blue">Massachusetts </font>law that places     <font color="blue">directors</font> of publicly-held <font color="blue">Massachusetts </font><font color="blue">corporation</font>s into three classes of     nearly equal sizes with staggered terms, thereby permitting only one-third     of the board of <font color="blue">directors</font> to be <font color="blue">elected at once</font></td>
    </tr>
    <tr>
      <td>In addition, with certain     <font color="blue">exceptions</font>,  <font color="blue">Massachusetts </font><font color="blue">law prohibits</font> a publicly-held <font color="blue">Massachusetts </font>    <font color="blue">corporation</font> from engaging in a business <font color="blue">combination transaction with</font> an     “interested  stockholder”  for a period of <font color="blue">three years</font></td>
    </tr>
    <tr>
      <td>An “interested     stockholder” is a person who owns 5prca or more of the <font color="blue">outstanding voting stock</font>     of the <font color="blue">corporation</font></td>
    </tr>
    <tr>
      <td>Finally, our by-laws include a <font color="blue">provision excluding us</font>     from the <font color="blue">applicability</font> of a <font color="blue">Massachusetts </font>statute that denies <font color="blue">voting rights</font>     to any person acquiring 20prca or more of the <font color="blue">outstanding voting stock</font> of a     <font color="blue">corporation</font>, unless such <font color="blue">voting rights</font> are <font color="blue">approved by</font> a majority of the     <font color="blue">corporation</font>’s disinterested <font color="blue"><font color="blue">shareholder</font>s</font></td>
    </tr>
    <tr>
      <td>Our by-laws may be <font color="blue">amended at</font> any     time to subject us to this <font color="blue">statute prospectively</font></td>
    </tr>
  </tbody>
</table>